hydrazine has been researched along with Chronic Hepatitis C in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 20 (95.24) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Al-Ramadhani, HM; Alzubiedi, S; Melhim, SB; Saleh, MI | 1 |
| Aguilar, C | 1 |
| Afdhal, NH; Bakulin, I; Brainsky, A; Campbell, FM; Chen, PJ; Dusheiko, GM; Geib, J; Giannini, EG; Han, KH; Kamel, YM; Lawitz, E; Mohsin, A; Patwardhan, R; Poordad, F; Rodriguez-Torres, M; Rugina, S; Shiffman, ML; Tayyab, GU; Theodore, D; Vasey, SY | 1 |
| Feld, JJ; Leber, A | 1 |
| Deng, H; Ji, F; Li, Z | 1 |
| Desborough, MJ; Jairath, V | 1 |
| Afdhal, NH; Theodore, D | 1 |
| Janssen, HL; Maan, R; Veldt, BJ | 1 |
| Ince, AT | 1 |
| Fang, L; Hussaini, A; Kleha, JF; Theodore, D; Wire, MB | 1 |
| Cipăian, RC; Mihăilă, RG | 1 |
| Burness, CB | 1 |
| Farrell, C; Thapar, M; Wire, MB; Zhang, J | 1 |
| Anter, HA; Khanfar, AA; Obeidat, AR; Saleh, MI | 1 |
| Annichiarico, BE; Coretti, S; Giannini, EG; Lidonnici, D; Marchetti, M; Rodeghiero, F; Romano, F; Ruggeri, M; Sacchini, D | 1 |
| Almasio, PL; Boccaccio, V; Bruno, S; Giannini, EG; Russo, ML; Sewpaul, P | 1 |
| de Knegt, RJ; Maan, R; Veldt, BJ | 1 |
| Baysal, B; Danalioglu, A; Kayar, Y; Kocaman, O; Senturk, H | 1 |
| Chen, PJ; Giannini, EG; Grotzinger, KM; Rendas-Baum, R; Theodore, D; Younossi, ZM | 1 |
| McHutchison, JG; Patel, K; Tillmann, HL | 1 |
| Fujiyama, S; Hattori, T; Katsura, K; Kawaguchi, T; Komori, A; Nakamuta, M; Oketani, M; Sakisaka, S; Sasaki, Y; Sata, M; Seike, M; Tanaka, M; Watanabe, H | 1 |
4 review(s) available for hydrazine and Chronic Hepatitis C
| Article | Year |
|---|---|
Potential usefulness of thrombopoietin receptor agonists in haemophiliacs with thrombocytopaenia due to chronic liver disease.
Topics: Benzoates; Blood Platelets; Chronic Disease; Drug Dosage Calculations; Hemophilia A; Hemorrhage; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Platelet Count; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Risk Factors; Thrombocytopenia; Thrombopoietin | 2013 |
Eltrombopag in chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Blood Platelets; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Pyrazoles; Receptors, Thrombopoietin; Risk Factors; Signal Transduction; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2014 |
Eltrombopag: a review of its use in the treatment of thrombocytopenia in patients with chronic hepatitis C.
Topics: Benzoates; Hepatitis C, Chronic; Humans; Hydrazines; Pyrazoles; Thrombocytopenia | 2014 |
Management of Thrombocytopenia in Chronic Liver Disease: Focus on Pharmacotherapeutic Strategies.
Topics: Benzoates; Chronic Disease; Disease Management; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Pyrazoles; Receptors, Fc; Receptors, Thrombopoietin; Recombinant Fusion Proteins; Thiazoles; Thiophenes; Thrombocytopenia; Thrombopoietin | 2015 |
6 trial(s) available for hydrazine and Chronic Hepatitis C
| Article | Year |
|---|---|
Bayesian Population Pharmacokinetic Modeling of Eltrombopag in Chronic Hepatitis C Patients.
Topics: Antiviral Agents; Bayes Theorem; Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Models, Biological; Pyrazoles; Thrombocytopenia | 2019 |
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Drug Administration Schedule; Female; Follow-Up Studies; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Induction Chemotherapy; Intention to Treat Analysis; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Maintenance Chemotherapy; Male; Middle Aged; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Treatment Outcome; Young Adult | 2014 |
Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir.
Topics: Adult; Area Under Curve; Benzoates; Calcium; Cross-Over Studies; Diet; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Oligopeptides; Proline; Purpura, Thrombocytopenic; Pyrazoles; Receptors, Thrombopoietin; Serine Proteinase Inhibitors; Young Adult | 2014 |
Eltrombopag dose predictors in thrombocytopenic subjects with hepatitis C virus infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Female; Hepatitis C, Chronic; Humans; Hydrazines; Male; Middle Aged; Pyrazoles; Thrombocytopenia; Treatment Outcome; Young Adult | 2015 |
12 weeks of interferon-based therapy is feasible in patients with hepatitis C-related cirrhosis and thrombocytopenia: A post hoc analysis of eltrombopag studies.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antiviral Agents; Benzoates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Hydrazines; Interferon-alpha; Liver Cirrhosis; Male; Middle Aged; Multivariate Analysis; Pyrazoles; Ribavirin; Risk Factors; Severity of Illness Index; Thrombocytopenia; Treatment Outcome | 2015 |
Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study.
Topics: Adult; Aged; Aged, 80 and over; Benzoates; Chronic Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hematologic Agents; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Hydrazines; Liver Diseases; Male; Middle Aged; Platelet Count; Pyrazoles; Thrombocytopenia; Treatment Outcome | 2012 |
11 other study(ies) available for hydrazine and Chronic Hepatitis C
| Article | Year |
|---|---|
Does eltrombopag really ENABLE SVR?
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Eltrombopag for thrombocytopenic patients with hepatitis C virus infection and cirrhosis.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Is treatment of moderate thrombocytopenia indicated for patients with HCV infection and cirrhosis?
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Reply: To PMID 24126097.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Eltrombopag for thrombocytopenic patients with chronic HCV infection.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Do we have to worry for thrombocytopenia during treatment of hepatitis C.
Topics: Antiviral Agents; Benzoates; Female; Hematologic Agents; Hepatitis C, Chronic; Humans; Hydrazines; Liver Cirrhosis; Male; Pyrazoles; Thrombocytopenia | 2014 |
Modeling and simulation support eltrombopag dosing in thrombocytopenic patients with chronic HCV infection.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Blood Platelets; Case-Control Studies; Computer Simulation; Drug Administration Schedule; Drug Dosage Calculations; Drug Interactions; Female; Hepatitis C, Chronic; Humans; Hydrazines; Interferon alpha-2; Interferon-alpha; Linear Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Platelet Count; Polyethylene Glycols; Polypharmacy; Pyrazoles; Recombinant Proteins; Thrombocytopenia; Thrombopoiesis; Young Adult | 2015 |
Economic assessment of eltrombopag in the treatment of thrombocytopenia.
Topics: Antiviral Agents; Benzoates; Cost-Benefit Analysis; Disease Progression; Hepatitis C, Chronic; Humans; Hydrazines; Markov Chains; Pyrazoles; Quality-Adjusted Life Years; Thrombocytopenia | 2015 |
Eltrombopag: How secure in triple therapy of HCV?
Topics: Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Middle Aged; Pyrazoles; Thrombocytopenia | 2015 |
Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.
Topics: Adult; Aged; Antiviral Agents; Benzoates; Female; Hepatitis C, Chronic; Humans; Hydrazines; Interferons; Liver Cirrhosis; Male; Middle Aged; Pyrazoles; Quality of Life; Surveys and Questionnaires; Thrombocytopenia; United States | 2016 |
Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C.
Topics: Antiviral Agents; Benzoates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hydrazines; Intercellular Signaling Peptides and Proteins; Interferon alpha-2; Interferon-alpha; Platelet Count; Polyethylene Glycols; Pyrazoles; Recombinant Proteins; Ribavirin; Thrombocytopenia; Thrombopoiesis; Treatment Outcome | 2009 |